LKFT

Lakefront Biotherapeutics NV

Healthcare · USD

Set alert

Price alert · LKFT

All alert types
32.28 USD -0.05 -0.15%
As of Oct 30, 2026 Extended hours 32.28 0.00%
Bid
32.26 × 2
Ask
32.30 × 2
32.06 Day range 32.76
26.08 52-week range 34.64
YTD
-1.28%
1 year
+3.00%
Open
32.42
Prev close
32.33
Mkt cap
2.13B
Vol
164.06K
Avg vol
285.76K
EPS
10.52
P/E
3.07
Div yield
0.00%
More statistics
Low
32.06
High
32.76
Forward P/E
-27.11
Beta
0.06
Short ratio
3.95
Inst. own
23.68%
Dividend
0.00
Ex-div date
Earnings
Nov 11, 2026
50-d avg
29.41
200-d avg
29.93
1y target
30.34

5D chart

Chart tools
Interval

Chart is warming up

The five-day price history for LKFT has not been loaded yet. Try again in a moment.

Financial health

Altman Z-Score

14.65 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

5 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

FMP rating

A+4 / 5 overall

  • DCF 1
  • Return on Equity 5
  • Return on Assets 5
  • Debt / Equity 4
  • P/E 4
  • P/B 5

Valuation

P/E 5.7×
FY 2021: -26.3×FY 2022: -12.5×FY 2023: 11.7×FY 2024: 23.7×FY 2025: 5.7×
FY 2021 5y median 5.7× FY 2025
P/S 1.6×
FY 2021: 11.6×FY 2022: 11.3×FY 2023: 10.3×FY 2024: 6.4×FY 2025: 1.6×
FY 2021 5y median 10.3× FY 2025
P/B 0.6×
FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 0.6×
FY 2021 5y median 0.0× FY 2025
P/FCF -6.8×
FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: -6.8×
FY 2021 5y median 0.0× FY 2025
EV/EBITDA 4.9×
FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 4.9×
FY 2021 5y median 0.0× FY 2025
EV/Sales 1.6×
FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 1.6×
FY 2021 5y median 0.0× FY 2025
FCF Yield -14.8%
FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: -14.8%
FY 2021 5y median 0.0% FY 2025

Profitability

Gross Margin 97.3%
FY 2021: -36.7%FY 2022: 100.0%FY 2023: 100.0%FY 2024: 87.4%FY 2025: 97.3%
FY 2021 5y median 97.3% FY 2025
Operating Margin 45.1%
FY 2021: -73.2%FY 2022: -54.3%FY 2023: -36.8%FY 2024: -68.3%FY 2025: 45.1%
FY 2021 5y median -54.3% FY 2025
Net Margin 28.9%
FY 2021: -44.0%FY 2022: -90.4%FY 2023: 88.3%FY 2024: 26.9%FY 2025: 28.9%
FY 2021 5y median 26.9% FY 2025
ROE 9.9%
FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 9.9%
FY 2021 5y median 0.0% FY 2025
ROIC 15.4%
FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 15.4%
FY 2021 5y median 0.0% FY 2025
ROA 9.4%
FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 9.4%
FY 2021 5y median 0.0% FY 2025

Growth (YoY)

Revenue 303.5%
FY 2021: 0.0%FY 2022: 2.9%FY 2023: -0.6%FY 2024: 15.0%FY 2025: 303.5%
FY 2021 FY 2025
Operating Income 366.2%
FY 2021: 0.0%FY 2022: 23.6%FY 2023: 32.7%FY 2024: -113.4%FY 2025: 366.2%
FY 2021 FY 2025
EPS (diluted) 334.8%
FY 2021: 0.0%FY 2022: -80.4%FY 2023: 196.7%FY 2024: -65.1%FY 2025: 334.8%
FY 2021 FY 2025
Free Cash Flow 0.0%
FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2021 FY 2025

Financial Health

Current Ratio 20.1×
FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 20.1×
FY 2021 5y median 0.0× FY 2025
Quick Ratio 20.0×
FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 20.0×
FY 2021 5y median 0.0× FY 2025
Debt / Equity 0.0×
FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 0.0×
FY 2021 5y median 0.0× FY 2025
Net Debt / EBITDA -0.2×
FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: -0.2×
FY 2021 5y median 0.0× FY 2025
Interest Coverage 226×
FY 2021: -19.7×FY 2022: -14.3×FY 2023: -49.9×FY 2024: -207×FY 2025: 226×
FY 2021 5y median -19.7× FY 2025

Dividends

Dividend Yield 0.0%
FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2021 5y median 0.0% FY 2025

Annual · latest fiscal year ends 2025-12-31